ArticleBMC cancer2025
Correlation of clinical presentation with prognosis in oral squamous cell carcinoma associated with oral submucous fibrosis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global expert consensus on oral submucous fibrosis: Standardizing care, surveillance, and prevention strategies.Journal of oral and maxillofacial pathology : JOMFPArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral squamous cell carcinoma (OSCC) associated with oral submucous fibrosis (OSMF) constitutes a clinicopathologically distinct entity in context to younger age of presentation, better histological grade of tumor differentiation, and lower risk of nodal metastasis. This study is intended to provide the basis of clinical presentation of OSCC associated with OSMF to consider a clinicopathologically unique entity compared to OSCC without OSMF.
methodsThe cohort of 320 OSCC patients was divided into two groups based on the association of OSMF. Group one, OSCC without OSMF (n = 166), whereas Group two, OSCC associated with OSMF (n = 154). The varied clinical presentation were categorized as, erythroplakic, erythro-leukoplakic, ulcerative/endophytic, ulcero-proliferative, and proliferative/exophytic. The variations in clinical presentation between the OSCC without OSMF and OSCC associated with OSMF groups were assessed using one-way ANOVA and the Tukey's HSD test.
resultsGroup one cohort presented with, significantly high number of cases clinically as ulcerative/endophytic 72 (43.4%) followed by ulcero-proliferative 53 (31.9%), erythro-leukoplakic 30 (18.1%), proliferative/exophytic 8 (4.8%) and erythroplakic 3 (1.8%). Whereas in Group two, significantly high number of cases clinically presented as nearly equal number of ulcero-proliferative 55 (35.7%) and proliferative/exophytic 50 (32.5%) followed by ulcerative/endophytic 25 (16.2%), erythro-leukoplakic 18 (11.7%) and erythroplakic 6 (3.9%) (p < 0.001).
conclusionSignificantly high number of cases of OSCC associated with OSMF clinically presented as ulcero-proliferative and proliferative/exophytic. This characteristic clinical presentation may contribute in early detection and diagnosis by providing considerable period for recognition and treatment planning and thus better prognosis in OSCC associated with OSMF cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.